RESULTS: We identified 4,800 advanced stage prostate cancer patients. Of these, 81% were white, 12% were African American, and 7% were Hispanic. The level of continuity of care varied between racial and ethnic groups. For African American patients, higher level of COC was associated with a reduction of 22% in the hazard of all-cause mortality, 26% in the hazard of prostate cancer specific mortality, 12% in the number of ER visits, 8% in the number of inpatient visits, and 5% in cost of care, comparted to white patients. On the other hand, the level of COC was not associated with outcomes for Hispanic patients.
INTRODUCTION AND OBJECTIVES:
Objectives of this study is to evaluate the natural history of PSA-change by age using the big data over 260,000 men in Japanese population which have been collected in the health-management service by Kyoto Industrial Health Association.
METHODS: Between 2007 and 2017, a total of 263,073 men participated a medical health examination including PSA screening test conducted by Kyoto Industrial Health Association in Kyoto, Japan. Of those, we excluded the men who had already diagnosed with prostate cancer and who had continued prostate cancer treatment. The histogram of PSA value per each age were prepared and PSA slope-curves were developed to demonstrate the 25%, median (50%), 75%, 90%, or 95% value of PSA in each age. The age ranged from 16 to 98 years (median, 54 years). The total number of the men with 16-39, 40-49, 50-59, 60-69, and 70-98 years were 29,283, 52,900, 107,742, 58,736, and 13,978, respectively. RESULTS: The total number of examinees excluding the clinically diagnosed prostate cancer was 262,639. The median (50%) PSA of the age group of 40s, 50s, and 60s was 0.72, 0.80, and 0.97 ng/ml, respectively. Fig 1 showed the PSA slope-curves for 25, 50, 75, 90, and 95 percentiles of PSA value by age, respectively. Although the PSA slope-curves showed a steep rise after age of 45 years, such sharp rise was especially recognized in the curve of 75, 90, and 95 percentiles, but not in that of 25 and 50 percentiles. When the 90 or greater percentile of PSA value was defined as possible high-risk group for clinically significant cancer or development of high-volume prostate hypertrophy, we found the cut-off value for PSA-velocity in age-range of 40-49 was 0.034ng/ml/year. When we focused on the 50 percentile of PSA value in order to find the natural history of PSA velocity, we found the significant difference in comparison between average PSA velocity in age-range of 50s, vs. 60s were 0.01 vs. 0.07 ng/ml/year (p<0.0001).
CONCLUSIONS: The natural history of PSA change in Japanese population were demonstrated with analyzing of a big data from 16 to 98 years old. This big data analysis could suggest the risk percentile for clinical prostate cancer or development of prostate hypertrophy as well as PSA velocity by age in Japanese population. METHODS: We focused on 1,345,561 PCa patients diagnosed between 2004-2015 within the NCDB. The cases included nonvariant PCa, and 5 rare variants of adenocarcinoma, namely, ductal, neuroendocrine (NEC), mucinous, signet ring cell (SRC), and adenosquamous PCa. Characteristics at presentation for each variant were compared with nonvariant PCa. Regression analyses tested the effect of histological subtype on OS.
RESULTS: Overall, 5,062 (0.38%) patients presented with rarevariant PCa. All rare variants presented with an advanced local stage (Stage ! cT3 43.4%, 42.2%, 18.9%, 16%, and 9.2%, in NEC, adenosquamous, ductal, SRC, and mucinous variants, respectively), compared to 5.9% in nonvariant PCa (all p<0.001; Table 1 ). Metastatic disease was most common with NEC (62.9%), followed by adenosquamous (31.1%), SRC (10.3%), and ductal (9.8%) variants, compared to 4.2% in nonvariant PCa (all p<0.001). Metastatic disease in mucinous (3.3%) was similar to nonvariant PCa (p [ 0.15). SRC, mucinous, and ductal variants presented with a significantly higher PSA (Median 9.0, 6.7, and 6.6, respectively vs. 6.2 ng/ml in nonvariant PCa; all p < 0.001), and higher biopsy grade (Grade group ! 4 (34.7%, 11.2%, and 27%, respectively vs. 8.6% in nonvariant PCa; all p < 0.001). At a median follow up of 5.3 years, estimated OS was highest in mucinous variant (88.7%), followed by nonvariant (86.3%), ductal (75.2%), SRC (66.2%), adenosquamous (20.5%), and NEC PCa (13.1%). After adjusting for covariates, regression analyses confirmed variant histology to be an independent predictor of OS.
CONCLUSIONS: There are differences in the presentation and OS among rare variants of PCa. NEC, adenosquamous, signet ring cell, and ductal variants more commonly present with metastatic disease. All variants present with a higher local stage than nonvariant PCa. NEC variant is associated with the worst, and mucinous variant with the best OS.
In the era of opioid crisis, substance use among elderly prostate cancer needs serious consideration. The study objective was to analyze the association between behavioral treatments for substance use and mortality among elderly Medicare patients with advanced stage prostate cancer and substance use disorder (including opioids).
METHODS: The Surveillance, Epidemiological, and Results (SEER)-Medicare linked databases between 2000 and 2013 were used. From the cohort of men diagnosed with advanced stage prostate cancer between 2001 and 2008, we identified those with a diagnosis of substance use (including opioids). For this cohort of elderly advanced prostate cancer patients who were substance users, we used Medicare claims to determine behavioral treatments for substance use such as psychotherapy (group or individual), drug and alcohol detoxification, case management, and behavioral health counseling (group or individual). Association between treatment for substance use and five-year mortality was analyzed using Cox regression models.
RESULTS: Of the 3,100 elderly with advanced prostate cancer and substance use disorder, less than 5% had a claim related to behavioral treatment for substance use in the five-year period following their prostate cancer diagnosis. Demographic and clinical attributes were comparable between those receiving behavioral treatment for substance use vs. those not receiving behavioral treatment for substance use. Cox regression results indicated that behavioral treatment for substance use was associated with lower hazard of allcause mortality (HR[0.72, 95% CI[ 0.47, 0.97) , and lower prostate cancer-specific mortality (HR[0.83, 95% CI[ 0.69, 0.94 ), compared to those not receiving behavioral treatment for substance use.
CONCLUSIONS: In elderly advanced stage prostate cancer patients with substance use disorder (including opioids), behavioral treatment for substance use appears to result in survival benefit. Many patients with advanced prostate cancer experience cancer related pain and impaired outcomes. However, the utilization of behavioral treatments for substance use remains low. Along with policies to effectively screen and treat substance use in elderly prostate cancer patients, policies for enhancing utilization of substance use treatment by elderly cancer patients are needed. Health Administration (VHA) cares for patients with prostate cancer with a higher burden of comorbidity than seen in the community. It can be challenging to select appropriate management for patients with increasing comorbidity burden without relevant survival data. Although many models exist to predict life expectancy in men with prostate cancer, few are specific to the VHA population or easily implemented in the clinic setting.
Source of
METHODS: Using the national VHA electronic health records, we identified all patients 18 years or older diagnosed with prostate cancer between 2000 and 2013. Patient demographics, comorbidities, and tumor staging information were abstracted. Overall survival information was calculated using the VA National Death Index with follow-up through 2015. We stratified patients by treatment type, number of comorbidities and D'Amico Risk Classification. We plotted visual estimates of overall survival using Kaplan-Meier methods and represented 10-year life expectancy cut-offs in table and heat map formats.
RESULTS: We identified 181,009 total patients, of whom 126,461 had complete oncologic data. The majority of patients were 60-74 years of age with a median of one comorbidity, and 38% were diagnosed with low risk prostate cancer. Kaplan-Meier analysis illustrated the negative impact of increasing comorbidities and cancer risk on survival, summarized further in table format.
CONCLUSIONS: Life expectancy estimates are essential to providing high-quality patient-centered prostate cancer care. We have developed an accessible tool to enhance medical decision-making for VHA patients with prostate cancer that can be easily adopted into routine clinical use. 
